

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU BIOPHARMA CO., LTD.
樂普生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2157)

POLL RESULTS OF THE 2023 ANNUAL GENERAL MEETING
HELD ON JUNE 19, 2024

References are made to the notice (the “**Notice**”) and the circular (the “**Circular**”) of the 2023 annual general meeting (the “**AGM**”) of the Company both dated May 28, 2024. Capitalised terms used herein shall have the same meanings as those defined in the Notice and the Circular unless the context requires otherwise.

ATTENDANCE AT THE AGM

The AGM was chaired by Dr. Pu Zhongjie, the chairman of the Board and an executive Director, and was successfully held at United Conference Centre, 10/F., United Centre, 95 Queensway, Hong Kong on Wednesday, June 19, 2024 at 2:00 p.m.. The AGM was convened in accordance with the requirements of the relevant laws and regulations of the PRC and the Articles of Association, and the poll results of the AGM are lawful and valid.

The Board is pleased to announce that all the resolutions proposed as set out in the Notice were duly passed by the Shareholders by way of poll at the AGM.

POLL RESULTS OF THE AGM

The poll results in respect of all the resolutions proposed at the AGM are as follows:

ORDINARY RESOLUTIONS		NO. OF SHARES VOTED (%)		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the resolution on the report of the Board of Directors of the Company for the year 2023.	1,177,214,558 (99.997537%)	0 (0.000000%)	29,000 (0.002463%)
2.	To consider and approve the resolution on the report of the Board of Supervisors of the Company for the year 2023.	1,177,120,558 (99.997536%)	0 (0.000000%)	29,000 (0.002464%)

ORDINARY RESOLUTIONS		NO. OF SHARES VOTED (%)		
		FOR	AGAINST	ABSTAIN
3.	To consider and approve the resolution on the annual report of the Group for the year 2023.	1,177,120,558 (99.997536%)	0 (0.000000%)	29,000 (0.002464%)
4.	To consider and approve the resolution on the financial accounts report of the Group for the year 2023.	1,177,120,558 (99.997536%)	0 (0.000000%)	29,000 (0.002464%)
5.	To consider and approve the resolution on the financial budget of the Group for the year 2024.	1,174,676,040 (99.789872%)	2,444,518 (0.207664%)	29,000 (0.002464%)
6.	To consider and approve the resolution on the annual profit distribution plan of the Company for the year 2023.	1,177,120,558 (99.997536%)	0 (0.000000%)	29,000 (0.002464%)
7.	To consider and approve the re-appointment of PricewaterhouseCoopers as the auditor of the Company for 2024, for a term commencing from the date of approval at the AGM until the conclusion of the 2024 annual general meeting of the Company, and authorize the Board to determine the specific matters in relation to such re-appointment, including but not limited to their remunerations.	1,177,120,558 (99.997536%)	0 (0.000000%)	29,000 (0.002464%)
SPECIAL RESOLUTION		NO. OF SHARES VOTED (%)		
		FOR	AGAINST	ABSTAIN
8.	To consider and approve the resolution on the grant of a general mandate to the Board to issue, allot and deal with the additional Shares.	1,169,246,972 (99.328668%)	7,873,586 (0.668868%)	29,000 (0.002464%)

As more than one-half of the votes were cast in favour of the resolutions numbered 1 to 7 above, these resolutions were duly passed as ordinary resolutions of the Company.

As more than two-thirds of the votes were cast in favour of the resolution numbered 8 above, this resolution was duly passed as a special resolution of the Company.

Notes:

- As at the date of the AGM, the total number of issued ordinary Shares was 1,710,614,838 Shares (including 1,656,346,474 H Shares and 54,268,364 Domestic Shares), which represented the total number of Shares entitling the Shareholders to attend and vote on the proposed resolutions at the AGM.
- There were no Shareholders, who, pursuant to Rule 13.40 of the Listing Rules, were required to abstain from voting in favour of any of the proposed resolutions at the AGM, nor were there any Shareholders who were required under the Listing Rules to abstain from voting.

3. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.
4. The total number of issued Shares held by the Shareholders in person or their proxies who have attended the AGM and are entitled to vote is 1,177,243,558 Shares, representing approximately 68.82% of the total number of issued Shares as at the date of the AGM.
5. The Company's H Shares registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.
6. All Directors attended the AGM in person or via electronic means.

By order of the Board
Lepu Biopharma Co., Ltd.
Dr. Pu Zhongjie
Chairman of the Board and Executive Director

Shanghai, the PRC
June 19, 2024

As at the date of this announcement, the Board comprises Dr. Pu Zhongjie (chairman) and Dr. Sui Ziye (chief executive officer) as executive Directors; Mr. Yang Hongbing and Ms. Pu Jue as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive Directors.